heart failure therapeutics on thebasisofabiased ligand of theangiotensin-2 type 1 receptor. Rationale and design of the blast-ahf study (biased ligand of the angiotensin receptor study in acute heart failure).

JACC: Heart Failure

Volumn 3, Issue 3, 2015, Pages 193-201

[No Author Info available]

Author keywords

BLAST AHF; NT proBNP; TRV027

Indexed keywords

ALISKIREN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BETA ARRESTIN 1; BETA ARRESTIN 2; ENALAPRILAT; FUROSEMIDE; G PROTEIN COUPLED RECEPTOR; LOOP DIURETIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC ACID DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; TRV 027; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ARTERIAL PRESSURE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BREATHING RATE; CARDIOVASCULAR MORTALITY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; GLOMERULUS FILTRATION; HEALTH CARE QUALITY; HEART OUTPUT; HEART PERFORMANCE; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; HOSPITAL READMISSION; HUMAN; HYPOTENSION; KIDNEY BLOOD FLOW; LENGTH OF STAY; LUNG EDEMA; MORBIDITY; MOUTH TEMPERATURE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OXYGEN SATURATION; OXYGEN SUPPLY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; PUBLIC HEALTH; PULMONARY ARTERY OCCLUSION PRESSURE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCORING SYSTEM; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VITAL SIGN; ACUTE DISEASE; DRUG EFFECTS; HEART FAILURE; METABOLISM; PROCEDURES;

ACUTE DISEASE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 84924982209     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.09.008     Document Type: Review

References (39)

1. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013, 127:e6-e245.
2. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 2012, 33:1787-1847.
3. Felker G.M., Pang P.S., Adams K.F., et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 2010, 3:314-325.
4. Cotter G., Davison B. Intravenous therapies in acute heart failure-lack of effect or lack of wellpowered studies?. Eur J Heart Fail 2014, 16:355-357.
5. Allen L.A., Hernandez A.F., O'Connor C.M., Felker G.M. End points for clinical trials in acute heart failure syndromes. JAm Coll Cardiol 2009, 53:2248-2258.
6. Packer M., Carson P., Elkayam U., et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 Study (Prospective Randomized Amlodipine Survival Evaluation 2). JAm Coll Cardiol HF 2013, 1:308-314.
7. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. NEngl J Med 2011, 365:32-43.
8. Massie B.M., O'Connor C.M., Metra M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. NEngl J Med 2010, 363:1419-1428.
9. Teerlink J.R., Cotter G., Davison B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013, 381:29-39.
10. Vaduganathan M., Greene S.J., Ambrosy A.P., Gheorghiade M., Butler J. The disconnect between phase II and phase III trials of drugsfor heart failure. Nat Rev Cardiol 2013, 10:85-97.
11. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000, 355:1575-1581. ACE-InhibitorMyocardial Infarction Collaborative Group.
12. Lee V.C., Rhew D.C., Dylan M., Badamgarav E., Braunstein G.D., Weingarten S.R. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004, 141:693-704.
13. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left-ventricular dysfunction with andwithout congestive-heart-failure-a substudy of the Studies of Left-Ventricular Dysfunction (SOLVD). Circulation 1990, 82:1724-1729.
14. Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival StudyII (CONSENSUS II). NEngl J Med 1992, 327:678-684.
15. Annane D., Bellissant E., Pussard E., et al. Placebo-controlled, randomized, double-blind study of intravenous enalaprilat efficacy and safety in acute cardiogenic pulmonary edema. Circulation 1996, 94:1316-1324.
16. Hirschl M.M., Binder M., Bur A., et al. Clinical evaluation of different doses of intravenous enalaprilat in patients with hypertensive crises. Arch Intern Med 1995, 155:2217-2223.
17. Gheorghiade M., Böhm M., Greene S.J., et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013, 309:1125-1135.
18. Violin J.D., Dewire S.M., Barnes W.G., Lefkowitz R.J. Gprotein-coupled receptor kinase and beta-arrestin-mediated desensitization of the angiotensin II type 1A receptor elucidated by diacylglycerol dynamics. JBiol Chem 2006, 281:36411-36419.
19. DeWire S.M., Ahn S., Lefkowitz R.J., Shenoy S.K. Beta-arrestins and cell signaling. Annu Rev Physiol 2007, 69:483-510.
20. Rajagopal S., Rajagopal K., Lefkowitz R.J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010, 9:373-386.
21. Touyz R.M., Schiffrin E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000, 52:639-672.
22. Fan G., Jiang Y.P., Lu Z., et al. Atransgenic mouse model of heart failure using inducible Galpha q. JBiol Chem 2005, 280:40337-40346.
23. Aplin M., Christensen G.L., Schneider M., et al. The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. Basic Clin Pharmacol Toxicol 2007, 100:289-295.
24. Ahn S., Kim J., Hara M.R., Ren X.R., Lefkowitz R.J. β-arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. JBiol Chem 2009, 284:8855-8865.
25. Kim K.S., Abraham D., Williams B., Violin J.D., Mao L., Rockman H.A. Beta-arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol 2012, 303:H1001-H1010.
26. Rajagopal K., Whalen E.J., Violin J.D., et al. β-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Nat Acad Sci U S A 2006, 103:16284-16289.
27. Monasky M.M., Taglieri D.M., Henze M., et al. The beta-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium. Am J Physiol Heart Circ Physiol 2013, 305:H856-H866.
28. Violin J.D., DeWire S.M., Yamashita D., et al. Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. JPharmacol Exp Ther 2010, 335:572-579.
29. Boerrigter G., Soergel D.G., Violin J.D., Lark M.W., Burnett J.C. TRV120027, a novel beta-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail 2012, 5:627-634.
30. Boerrigter G., Lark M.W., Whalen E.J., Soergel D.G., Violin J.D., Burnett J.C. Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 2011, 4:770-778.
31. Soergel D.G., Subach R.A., Cowan C.L., Violin J.D., Lark M.W. First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. JClin Pharmacol 2013, 53:892-899.
32. Soergel D., Subach R.A., James I.E., Cowan C.L., Gowen M., Lark M. TRV027, a beta-arrestin biased ligand at the angiotensin 2 type 1 receptor, produces rapid, reversible changes in hemodynamics in patients with stable systolic heart failure. JAm Coll Cardiol 2013, 61(Suppl 10):e683. (abstr).
33. Packer M., Colucci W.S., Fisher L., et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JAm Coll Cardiol HF 2013, 1:103-111.
34. Sun H., Davison B.A., Cotter G., Pencina M.J., Koch G.G. Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method. Circ Heart Fail 2012, 5:742-749.
35. Pang P.S., Cleland J.G., Teerlink J.R., et al. Aproposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008, 29:816-824.
36. Felker G.M., Maisel A.S. Aglobal rank end point for clinical trials in acute heart failure. Circ Heart Fail 2010, 3:643-646.
37. Pocock S.J., Ariti C.A., Collier T.J., Wang D. Thewin ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012, 33:176-182.
38. O'Brien P.C. Procedures for comparing samples with multiple endpoints. Biometrics 1984, 40:1079-1087.
39. Saville B.R., Herring A.H., Koch G.G. Arobust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data. Stat Med 2010, 29:75-85.